Cancer immunotherapy in the form of immune checkpoint inhibitors has led to a dramatic increase in the survival of patients with lung cancer across all stages. Over the past decade, the field has experienced rapid maturation; however, several challenges continue to complicate patient management. This...
TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer Zhaopei Liu ,Han Zeng &Zewei Wang Review Article|16 August 2021 Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers ...
Review Article | 19 April 2022 Engineered cellular immunotherapies in cancer and beyond Oncology is trailblazing the field of engineered cellular therapeutics. This Review discusses the goals of cellular immunotherapy in cancer, key challenges facing the field and strategies to overcome them—paving th...
Effectiveness of adjuvant immunotherapy in muscle-invasive urothelial cancer: A systematic review and meta-analysis of randomized controlled trials. Effectiveness of adjuvant immunotherapy in muscle-invasive urothelial cancer: A systematic review and meta-analysis of randomized controlled trials... IMMD Silva...
Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141:1018–28.https://doi.org/10.1002/ijc.30678. ...
Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review Janiczek, M.; Szylberg, L.; Kasperska, A.; Kowalewski, A.; Parol, M.; Antosik, P.; Radecka, B.; Marszałek, A. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. J. Immunol...
review enlightens the eminent immunotherapies used for veterinary patients. T cell checkpoint inhibitors, engineered T cells, cancer vaccines, and anti-B and anti-T cell antibodies are amongst the important immunotherapies used in human as well as veterinary patient. Inhibition of T cell checkpoint ...
. Although notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer
Esophageal cancer (EC) is one of the most common types of cancer worldwide and was ranked as the sixth leading cause of cancer-related deaths in 2020. When EC is localized or locally advanced, referred to as resectable EC, surgery is usually the preferre
W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010). CAS PubMed Google Scholar Graff, J. N. & Chamberlain, E. D. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. ...